Literature DB >> 6319165

Effect of an anti-murine transferrin receptor-ricin A conjugate on bone marrow stem and progenitor cells treated in vitro.

J Lesley, D L Domingo, R Schulte, I S Trowbridge.   

Abstract

A monoclonal antibody with specificity for murine transferrin receptor was conjugated with the toxic A subunit of ricin. The dose range, specificity, and kinetics of inhibition of protein synthesis of the conjugate were determined on the murine T-lymphoma cell line, BW5147. When toxin was present throughout the period of culture, in vitro myeloid (CFUc) and erythroid (CFUe and BFUe) bone marrow colonies were inhibited by doses of conjugate comparable to those that inhibit protein synthesis in murine cell lines (IC50 of 5 X 10(-11)M). Bone marrow exposed briefly (30 min to 6 h) to anti-transferrin receptor antibody-ricin A conjugate was assayed for myeloid (CFUc) and erythroid (CFUe and BFUe) progenitors in vitro and for in vivo spleen colony formation (CFUs). Only CFUe were depleted by this pulse exposure, consistent with the higher frequency of proliferating cells and transferrin receptor expression in the CFUe population relative to other progenitors.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6319165     DOI: 10.1016/0014-4827(84)90583-4

Source DB:  PubMed          Journal:  Exp Cell Res        ISSN: 0014-4827            Impact factor:   3.905


  12 in total

1.  An anti-transferrin receptor-avidin fusion protein exhibits both strong proapoptotic activity and the ability to deliver various molecules into cancer cells.

Authors:  Patrick P Ng; Jay S Dela Cruz; David N Sorour; James M Stinebaugh; Seung-Uon Shin; Daniel S Shin; Sherie L Morrison; Manuel L Penichet
Journal:  Proc Natl Acad Sci U S A       Date:  2002-07-29       Impact factor: 11.205

2.  High-yield isolation of functionally competent endosomes from mouse lymphocytes.

Authors:  B D Beaumelle; C R Hopkins
Journal:  Biochem J       Date:  1989-11-15       Impact factor: 3.857

3.  Analysis of lymphopoietic stem cells with a monoclonal antibody to the rat transferrin receptor.

Authors:  W A Jefferies; M R Brandon; A F Williams; S V Hunt
Journal:  Immunology       Date:  1985-02       Impact factor: 7.397

4.  Molecular events contributing to cell death in malignant human hematopoietic cells elicited by an IgG3-avidin fusion protein targeting the transferrin receptor.

Authors:  Patrick P Ng; Gustavo Helguera; Tracy R Daniels; Simon Z Lomas; Jose A Rodriguez; Gary Schiller; Benjamin Bonavida; Sherie L Morrison; Manuel L Penichet
Journal:  Blood       Date:  2006-06-27       Impact factor: 22.113

5.  Selection and characterization of transferrin receptor mutants using receptor-specific antibodies.

Authors:  J Lesley; R Schulte
Journal:  Immunogenetics       Date:  1986       Impact factor: 2.846

Review 6.  The transferrin receptor and the targeted delivery of therapeutic agents against cancer.

Authors:  Tracy R Daniels; Ezequiel Bernabeu; José A Rodríguez; Shabnum Patel; Maggie Kozman; Diego A Chiappetta; Eggehard Holler; Julia Y Ljubimova; Gustavo Helguera; Manuel L Penichet
Journal:  Biochim Biophys Acta       Date:  2011-08-05

7.  Long-term repopulation of hematolymphoid cells with only a few hemopoietic stem cells in mice.

Authors:  H Ogata; W G Bradley; M Inaba; N Ogata; S Ikehara; R A Good
Journal:  Proc Natl Acad Sci U S A       Date:  1995-06-20       Impact factor: 11.205

8.  Selection of cell lines resistant to anti-transferrin receptor antibody: evidence for a mutation in transferrin receptor.

Authors:  J F Lesley; R J Schulte
Journal:  Mol Cell Biol       Date:  1984-09       Impact factor: 4.272

Review 9.  Diphtheria toxin-based targeted toxin therapy for brain tumors.

Authors:  Yan Michael Li; Daniel A Vallera; Walter A Hall
Journal:  J Neurooncol       Date:  2013-05-22       Impact factor: 4.130

Review 10.  Targeted toxins in brain tumor therapy.

Authors:  Yan Michael Li; Walter A Hall
Journal:  Toxins (Basel)       Date:  2010-11-01       Impact factor: 5.075

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.